FIELD: medicine; biotechnology.
SUBSTANCE: described is a method for treatment of a patient with cancer expressing a tumour-associated antigenic protein MAGEA3, an isolated Maraba MG1 virus particle and a first virus. Said particle contains nucleic acid that is capable of expressing the tumour-associated antigenic protein MAGEA3. Said antigenic protein contains an amino acid sequence that is at least 70 % identical to SEQ ID NO: 1, and includes at least one tumour-associated MAGEA3 epitope selected from the group consisting of: FLWGPRALV (SEQ ID NO: 27), KVAELVHFL (SEQ ID NO: 28), EGDCAPEEK (SEQ ID NO: 35), KKLLTQHFVQENYLEY (SEQ ID NO: 36) and RKVAELVHFLLLKYR (SEQ ID NO: 37). Said antigen protein is able to induce an immune response in a specified patient in a heterologous prime-boost format. This first virus is an adenovirus containing nucleic acid capable of expressing the tumour-associated antigenic protein MAGEA3. Said antigenic protein contains an amino acid sequence that is at least 70 % identical to SEQ ID NO: 1, and includes at least one tumor-associated MAGE A3 epitope selected from the group consisting of: FLWGPRALV (SEQ ID NO: 27), KVAELVHFL (SEQ ID NO: 28), EGDCAPEEK (SEQ ID NO: 35), KKLLTQHFVQENYLEY (SEQ ID NO: 36) and RKVAELVHFLLLKYR (SEQ ID NO: 37). Described is an oncolytic heterologous viral prime-boost vaccine for treating a patient with cancer and the use of an isolated viral particle Maraba MG1 for the induction of an immune response in a patient in a heterologous prime-boost format for oncolytic viral therapy.
EFFECT: invention allows to expand the range of agents and methods used for oncolytic viral therapy.
33 cl, 9 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FMDV VACCINES BASED ON A RECOMBINANT ADENOVIRAL VECTOR AND USE THEREOF | 2017 |
|
RU2725495C2 |
| RECOMBINANT VACCINE AGAINST AVIAN FLU AND APPLICATION THEREOF | 2009 |
|
RU2559527C2 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| RECOMBINANT VACCINES AGAINST BLUETONGUE VIRUS, THEIR USE | 2011 |
|
RU2575599C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| PRIME-BOOST MODES INVOLVING INTRODUCTION OF AT LEAST ONE MRNA STRUCTURE | 2016 |
|
RU2742993C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| RECOMBINANT INFLUENZA VIRUS INTENDED FOR THE PREVENTION OF COVID-19 AND INFLUENZA, METHOD OF ITS PRODUCTION AND USE | 2022 |
|
RU2802058C1 |
| ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AS WELL AS FOR CANCER TREATMENT | 2015 |
|
RU2628690C2 |
| RECOMBINANT PSEUDO-ADENOVIRAL PARTICLE STRAIN EXPRESSING THE CHLAMYDIA TRACHOMATIS CHIMERIC GENE MBL-CT666, A METHOD FOR PREPARING IT, AN IMMUNOGENIC COMPOSITION FOR PROTECTION AGAINST HUMAN UROGENITAL CHLAMYDIOSIS | 2019 |
|
RU2721123C1 |
